Screening of New Tumor Drug Targets / Markers

Screening of anti-tumor drugs is an important part of the discovery and development of new drugs, and usually refers to the work in all stages from the sample to the activity detection to the efficacy of animal experiments. In the post-genomic era, target-based high-throughput drug screening models have become an important part of drug development plans. With the rapid development of combinatorial chemistry, genomics and proteomics, more and more targets and small molecular libraries are being used for drug screening. Drug screening models are an important condition for discovering new drugs. The establishment of new models will drive the emergence of new drugs. Creative Proteomics can provide customers with drug screening services at the molecular, cell, isolated specimen and overall animal level.It has established relatively mature research fields such as anti-tumor, immune disease, anti-inflammatory, cardiovascular disease, analgesia and diabetes. The drug screening model includes both a new, high-throughput primary screening model that is trace, fast, and highly automated, as well as an in-depth screening screening model at all levels, forming an efficient and multi-layered drug screening platform. Today, drug screening has broken through the traditional biological category and become a process that combines chemistry, biology, and engineering. It is believed that with the continuous improvement of target-based high-throughput drug screening methods and continuous improvement of equipment, high-throughput drug screening models will play a greater role in the development of new drugs.

Our Advantage

Mature and reliable experimental analysis platform of Screening of New Tumor Drug Targets / Markers: rich project experience, participation in major projects, high-level cooperation results published.

Based on high-quality data analysis, pre-research and verification of the contents and methods of analysis, it is indeed mature and feasible.